U.S. Phase 3 Clinical Trials Market Revenue, Leading Companies, Company Technology / Innovation, Diagnostic Testing Volume, Adoption Rates, Pricing Metrics, Supply Chain Performance, Competitive Positioning, and Industry Trends

Key Takeaways

Market Size & Growth Outlook

• Market size in 2025: USD 26.20 billion
• Estimated market size in 2026: USD 27.85 billion
• Projected market size by 2035: USD 48.27 billion
• CAGR (2026-2035): 6.30%

Regional Market Spotlight

• Northeast led the market with a 31.40% with USD 8.23 billion share in 2025.
• South accounted for 30.20% with USD 7.91 billion of the market in 2025 and is projected to be the fastest-growing region, at a CAGR of 6.84% from 2025 to 2035.
• West accounted for 22.80% with USD 5.97 billion of the market in 2025.

Segmental Spotlight

• By indication, the oncology accounted for 30.40% with USD 7.96 billion in 2025.
• By sponsor, the pharmaceutical companies accounted for 62.40% with USD 16.35 billion in 2025.
• By service type, the site management & monitoring accounted for 38.60% with USD 10.11 billion in 2025.
• By trial model, the traditional site-based accounted for 71.40% with USD 18.71 billion in 2025.

U.S. Phase 3 Clinical Trials Market Size and Forecast, 2025-2035 (USD Billion)

Note: 2025 is the base year; 2026-2035 values are forecasts.

Sources: Expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.

The U.S. Phase 3 clinical trials market is projected to grow from USD 26.20 billion in 2025 to USD 48.27 billion by 2035 because Phase 3 trials are the most expensive stage of drug development, and large late-stage pipelines in obesity, oncology and immunology keep spending in the United States rising. Large cardiometabolic outcome trials, oncology combination studies, CRO outsourcing, decentralised trial technologies and higher per-patient costs support steady growth, moderated by biotech funding cycles and efforts to make trials more efficient, lifting the market to USD 35.56 billion by 2030 and sustaining a CAGR of 6.30% from 2026 to 2035.

• Analyst View: We built the estimate from the number of active Phase 3 studies in the United States by indication, sponsor and service type, multiplied by average cost per study and per patient, using trial registry data and sponsor and CRO spending. Study volumes reflect pipelines, approvals and regulatory requirements, while costs reflect trial size, complexity and duration. The total was cross-checked against U.S. clinical trial market estimates and the reported phase mix, and against the revenues of leading CROs, which places our base year slightly above the highest credible comparable figure for Phase 3. The growth rate is based on evidence from pipeline and regulatory trends, moderated by efforts to control trial costs.

Market Trends

• Risk-based monitoring under ICH E6(R3).
• Hybrid and decentralised trial elements.
• AI-assisted site selection and recruitment.
• Large cardiometabolic outcome trials.
• Biotech-sponsored late-stage programmes.
• Diversity and inclusion in enrolment.

Drivers, Restraints and Opportunities

Driver

Late-stage pipelines are large. Obesity and cardiometabolic trials are huge. Oncology combinations multiply studies. Sponsors outsource to CROs. Regulators require robust evidence.

Restraint

Trials are costly and slow. Recruitment is difficult. Biotech funding is cyclical. Site staff shortages. Regulatory complexity across regions.

Opportunity

Decentralised elements improve access. AI improves recruitment. Adaptive designs reduce costs. Diverse populations expand site networks. Real-world data can support trial design.

Market Segmentation: 2025 Share and Size

U.S. Phase 3 Clinical Trials Market by Indication 2025 Share

Note: 2025 is the base year; 2035 values are forecasts.

Sources: Expert interviews, secondary sources, Precedence Research database, and Precedence Research analysts.

Oncology accounted for 30.40% with USD 7.96 billion in 2025, cardiovascular and metabolic for 16.60% with USD 4.35 billion, autoimmune and inflammatory for 12.80% with USD 3.35 billion, CNS for 12.20% with USD 3.20 billion, infectious diseases for 8.40% with USD 2.20 billion, and others for 19.60% with USD 5.14 billion.

Oncology: This segment accounted for 30.40% with USD 7.96 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 13.95 billion by 2035, expanding at a CAGR of 5.76% from 2026 to 2035. Oncology is the largest indication because cancer drugs dominate late-stage pipelines, including immunotherapy combinations, antibody-drug conjugates, and targeted therapies, and oncology studies require long follow-up, imaging, and biomarker testing.

Cardiovascular & Metabolic: This segment accounted for 16.60% with USD 4.35 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 9.09 billion by 2035, expanding at a CAGR of 7.66% from 2026 to 2035. Cardiovascular and metabolic studies, including obesity, diabetes, heart failure, and kidney disease outcome trials, are the fastest-growing indication because incretin and other cardiometabolic drugs require very large, long trials and post-approval outcome evidence.

Autoimmune & Inflammatory: This segment accounted for 12.80% with USD 3.35 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 6.09 billion by 2035, expanding at a CAGR of 6.16% from 2026 to 2035. Autoimmune and inflammatory studies cover rheumatoid arthritis, inflammatory bowel disease, psoriasis, atopic dermatitis, and lupus, with many new biologics and oral drugs in development.

CNS: This segment accounted for 12.20% with USD 3.20 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 5.81 billion by 2035, expanding at a CAGR of 6.16% from 2026 to 2035. CNS studies include Alzheimer's disease, depression, schizophrenia, migraine, and pain, which require large patient numbers and complex endpoints.

Infectious Diseases: This segment accounted for 8.40% with USD 2.20 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 4.00 billion by 2035, expanding at a CAGR of 6.16% from 2026 to 2035. Infectious disease studies include vaccines, antivirals, and antibiotics, where large vaccine trials can involve tens of thousands of participants.

Others: This segment accounted for 19.60% with USD 5.14 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 9.33 billion by 2035, expanding at a CAGR of 6.16% from 2026 to 2035. Others include respiratory, renal, ophthalmology, dermatology, women's health, and rare disease studies.

U.S. Phase 3 Clinical Trials Market by Sponsor 2025 Share & Size

Note: 2025 is the base year; 2035 values are forecasts.

Sources: Expert interviews, secondary sources, Precedence Research database, and Precedence Research analysts.

Pharmaceutical Companies accounted for 62.40% with USD 16.35 billion in 2025, biotechnology companies for 28.60% (USD 7.49 billion and medical device and others for 9.00% (USD 2.36 billion).

Pharmaceutical Companies: This segment accounted for 62.40% with USD 16.35 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 28.69 billion by 2035, expanding at a CAGR of 5.78% from 2026 to 2035. Pharmaceutical companies are the largest sponsors, running large global programmes and outsourcing much of the work to CROs.

Biotechnology Companies: This segment accounted for 28.60% with USD 7.49 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 15.28 billion by 2035, expanding at a CAGR of 7.38% from 2026 to 2035. Biotechnology companies are the fastest-growing sponsors because many late-stage assets now originate in biotech, and these companies rely heavily on full-service CROs.

Medical Device & Others: This segment accounted for 9.00% with USD 2.36 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 4.30 billion by 2035, expanding at a CAGR of 6.18% from 2026 to 2035. Medical device companies and others, including academic and government sponsors, run pivotal and post-market device studies and investigator-initiated trials.

U.S. Phase 3 Clinical Trials Market by Service Type 2025 Share

Note: 2025 is the base year; 2035 values are forecasts.

Sources: Expert interviews, secondary sources, Precedence Research database, and Precedence Research analysts.

Site Management and Monitoring accounted for 38.60% with USD 10.11 billion in 2025, patient recruitment and retention for 18.40% with USD 4.82 billion, data management and biostatistics for 14.20% with USD 3.72 billion, clinical supply and logistics for 11.20% with USD 2.93 billion, central lab and others for 9.00% with USD 2.36 billion and regulatory and medical writing for 8.60% with USD 2.25 billion.

Site Management & Monitoring: This segment accounted for 38.60% with USD 10.11 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 17.71 billion by 2035, expanding at a CAGR of 5.76% from 2026 to 2035. Site management and monitoring is the largest service, covering site selection, activation, investigator payments, and on-site and risk-based monitoring.

Patient Recruitment & Retention: This segment accounted for 18.40% with USD 4.82 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 10.08 billion by 2035, expanding at a CAGR of 7.66% from 2026 to 2035. Patient recruitment and retention is the fastest-growing service because enrolment is the main cause of delays, and sponsors use digital outreach, AI-based site selection, and patient support to speed it up.

Data Management & Biostatistics: This segment accounted for 14.20% with USD 3.72 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 6.76 billion by 2035, expanding at a CAGR of 6.16% from 2026 to 2035. Data management and biostatistics include electronic data capture, data cleaning, statistical analysis, and reporting.

Clinical Supply & Logistics: This segment accounted for 11.20% with USD 2.93 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 5.33 billion by 2035, expanding at a CAGR of 6.16% from 2026 to 2035. Clinical supply and logistics include manufacturing, packaging, labelling, and distribution of investigational products, including temperature-controlled supply.

Central Lab & Others: This segment accounted for 9.00% with USD 2.36 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 4.29 billion by 2035, expanding at a CAGR of 6.16% from 2026 to 2035. Central laboratory and other services include central lab testing, imaging reads, and biomarker analysis.

Regulatory & Medical Writing: This segment accounted for 8.60% with USD 2.25 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 4.10 billion by 2035, expanding at a CAGR of 6.16% from 2026 to 2035. Regulatory and medical writing include protocols, clinical study reports, and regulatory submissions.

U.S. Phase 3 Clinical Trials Market by Trial Model 2025 Share & Size

Note: 2025 is the base year; 2035 values are forecasts.

Sources: Expert interviews, secondary sources, Precedence Research database, and Precedence Research analysts.

Traditional Site-Based accounted for 71.40% with USD 18.71 billion in 2025, and hybrid and decentralized for 28.60% with USD 7.49 billion.

Traditional Site-Based: This segment accounted for 71.40% with USD 18.71 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 32.15 billion by 2035, expanding at a CAGR of 5.56% from 2026 to 2035. Traditional site-based trials remain dominant because most Phase 3 procedures require in-person visits at hospitals and clinics.

Hybrid & Decentralized: This segment accounted for 28.60% with USD 7.49 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 16.12 billion by 2035, expanding at a CAGR of 7.96% from 2026 to 2035. Hybrid and decentralised trials use remote visits, home nursing, eConsent and wearables. They are the fastest-growing model because they widen access and improve retention.

• Analyst View: Segment values were allocated by matching study volumes and costs to indication, sponsor, service type and trial model, using trial registry data and CRO revenue mixes. Oncology, pharmaceutical sponsors, site management and traditional trials lead, while cardiometabolic studies, biotech sponsors, recruitment services and hybrid models gain share.

Country Analysis

U.S. Phase 3 Clinical Trials Market by Country 2025 Share

Note: 2025 is the base year; 2035 values are forecasts.

Sources: Expert interviews, secondary sources, Precedence Research database, and Precedence Research analysts.

The Northeast accounted for 31.40% with USD 8.23 billion in 2025, the South for 30.20% with USD 7.91 billion, the West for 22.80% with USD 5.97 billion, and the Midwest for 15.60% with USD 4.09 billion. The Northeast leads, while the South is growing fastest.

Northeast: This region accounted for 31.40% with USD 8.23 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 14.51 billion by 2035, expanding at a CAGR of 5.84% from 2026 to 2035. The Northeast has the densest concentration of sponsors, academic medical centres, and investigative sites in Boston, New York, New Jersey, and Philadelphia.

South: This region accounted for 30.20% with USD 7.91 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 15.33 billion by 2035, expanding at a CAGR of 6.84% from 2026 to 2035. The South, including Texas, Florida, North Carolina, and Georgia, has large and diverse patient populations, many independent research sites, and growing CRO operations. It is the fastest-growing region as sponsors seek faster enrolment and more diverse participants.

West: This region accounted for 22.80% with USD 5.97 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 10.94 billion by 2035, expanding at a CAGR of 6.24% from 2026 to 2035. The West includes California's biotech hubs in the San Francisco Bay Area and San Diego, and major medical centres in Los Angeles and Seattle.

Midwest: This region accounted for 15.60% with USD 4.09 billion of the U.S. Phase 3 clinical trials market in 2025 and is projected to reach USD 7.49 billion by 2035, expanding at a CAGR of 6.24% from 2026 to 2035. The Midwest has large health systems and academic centres such as the Mayo Clinic, Cleveland Clinic, and university hospitals, and growing community research networks.

Analyst View: Regional shares were built from active study sites and spending in each region. The Northeast leads because of its sponsor and academic base. We assign the South the highest growth premium because sponsors are expanding there for faster and more diverse enrolment.

Competitive Landscape

Top 10 Companies in the U.S. Phase 3 Clinical Trials Market, 2025

Note: Company revenues and shares are 2025 estimates.

Sources: Company press releases, expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.

IQVIA led the U.S. Phase 3 clinical trials market with an estimated 12.21% of USD 3.20 billion of 2025 revenue, followed by Thermo Fisher (PPD) at 9.92% with USD 2.60 billion and ICON at 9.16% with USD 2.40 billion. IQVIA leads with the largest clinical development and real-world data business, combining site networks, analytics and technology. Thermo Fisher's PPD clinical research business and ICON are the next largest full-service CROs. Parexel, Syneos Health, Medpace, Fortrea and other providers compete through therapeutic expertise, biotech focus, site networks, functional services and regional strengths.

The top 10 companies accounted for an estimated 55.73% with USD 14.60 billion of 2025 revenue, while the remaining 44.27% with USD 11.60 billion was shared among smaller CROs, site networks, academic research organisations and in-house sponsor teams. The U.S. Phase 3 clinical trials market is moderately concentrated among large CROs, and competition centres on therapeutic expertise, site networks, recruitment speed, data and technology platforms, regulatory experience, quality and price. Sponsors increasingly use strategic partnerships with a few full-service providers.

Companies Ecosystem

The U.S. Phase 3 clinical trials ecosystem links sponsors with CROs, site networks, technology and data providers, central laboratories, regulators, ethics committees and patients.

Sources: Company press releases, expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.

Precedence Research Companies Quadrant

The Precedence Research Companies Quadrant positions key participants in the U.S. Phase 3 clinical trials market by market strength, reflecting revenue scale, market share and geographic reach, and by innovation and growth strategy, reflecting product portfolio breadth, R&D intensity and partnerships. Positions reflect each company's estimated 2025 revenue in this market and our assessment of its technology, therapeutic expertise and partnerships.

Sources: Company press releases, expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.

Leaders: IQVIA, Thermo Fisher (PPD), ICON, Parexel, Syneos Health and Medpace combine large revenue with global reach, broad therapeutic expertise and data and technology platforms.

Challengers: Fortrea has large operations but is restructuring or less differentiated.

Innovators: WCG and Worldwide Clinical Trials bring specialised therapeutic focus or real-world data capabilities.

Niche Players: Premier Research serves narrower regional or therapeutic segments.

Recent Developments

• In July 2025, the European Medicines Agency's adoption of ICH E6(R3) good clinical practice principles took effect, after ICH published the final guideline in January 2025, encouraging risk-based approaches that global sponsors are applying across U.S. and international Phase 3 programmes.

U.S. Phase 3 Clinical Trials Market Segments

By Indication

• Oncology
• Cardiovascular & Metabolic
• Autoimmune & Inflammatory
• CNS
• Infectious Diseases
• Others

By Sponsor

• Pharmaceutical Companies
• Biotechnology Companies
• Medical Device & Others

By Service Type

• Site Management & Monitoring
• Patient Recruitment & Retention
• Data Management & Biostatistics
• Clinical Supply & Logistics
• Central Lab & Others
• Regulatory & Medical Writing

By Trial Model

• Traditional Site-Based
• Hybrid & Decentralized

By Country

• Northeast
• South
• West
• Midwest

Research Methodology

The U.S. Phase 3 clinical trials market was defined as Phase 3 clinical trial spending, including sponsor and outsourced services, in the United States. The 2025 base year was built bottom-up from active Phase 3 studies, patients and costs by indication, sponsor, service type and region, and checked top-down against published clinical trial market estimates by phase and the revenues of leading CROs. Segment, regional and company values were allocated from indications, sponsors, services and regional study activity.

Key estimates were verified by cross-checking company disclosures, regulatory and industry data and published third-party estimates, and inputs that could not be reconciled were excluded. All segment, regional and company figures were reconciled to the same 2025 base year, and the 2026-2035 forecast, which applies a constant CAGR from the 2025 base, was recalculated and validated.

Analyst View: Overall Market

The U.S. Phase 3 clinical trials market is the largest component of clinical development spending, and its growth follows the size and complexity of late-stage pipelines. Our estimate links demand to study volumes and costs, so the forecast follows pipelines, outsourcing and trial efficiency. The main upside comes from cardiometabolic and oncology programmes, while the main risks are biotech funding and cost pressure.

Sources and References

• The FDA Law Blog. "The ICH E6(R3) Guideline: A Major Update to Good Clinical Practice". February 2025. Article. https://www.thefdalawblog.com/2025/02/the-ich-e6r3-guideline-a-major-update-to-good-clinical-practice/